BIOFIL CHEMICALS & PHARMACEUTICALS
|
BIOFIL CHEMICALS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.34 | 0.43 | 0.76 | 0.74 | 0.30 |
| CEPS(Rs) | 0.61 | 0.69 | 1.02 | 0.99 | 0.52 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 10.63 | 10.35 | 9.91 | 9.15 | 8.39 |
| Tax Rate(%) | 29.33 | 31.19 | 35.31 | 17.55 | 19.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 3.89 | 5.95 | 4.47 | 6.14 | 4.43 |
| EBIT Margin(%) | 2.78 | 4.72 | 5.56 | 5.34 | 3.29 |
| Pre Tax Margin(%) | 2.64 | 4.53 | 5.37 | 4.93 | 2.59 |
| PAT Margin (%) | 1.87 | 3.12 | 3.47 | 4.07 | 2.09 |
| Cash Profit Margin (%) | 3.29 | 5.03 | 4.62 | 5.44 | 3.66 |
| Performance Ratios | |||||
| ROA(%) | 2.24 | 2.69 | 3.28 | 3.63 | 1.99 |
| ROE(%) | 3.28 | 4.24 | 8.01 | 8.46 | 3.60 |
| ROCE(%) | 4.76 | 6.23 | 12.18 | 10.12 | 5.06 |
| Asset Turnover(x) | 1.20 | 0.86 | 0.95 | 0.89 | 0.96 |
| Sales/Fixed Asset(x) | 2.58 | 1.93 | 3.11 | 2.62 | 2.19 |
| Working Capital/Sales(x) | 3.46 | 2.86 | 5.33 | 6.20 | 6.89 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.39 | 0.52 | 0.32 | 0.38 | 0.46 |
| Receivable days | 168.17 | 198.88 | 239.55 | 256.53 | 197.31 |
| Inventory Days | 15.23 | 45.97 | 30.82 | 17.72 | 17.48 |
| Payable days | 88.15 | 154.25 | 235.08 | 248.78 | 161.80 |
| Valuation Parameters | |||||
| PER(x) | 120.33 | 134.67 | 86.06 | 9.98 | 22.30 |
| PCE(x) | 68.15 | 83.54 | 64.62 | 7.45 | 12.69 |
| Price/Book(x) | 3.90 | 5.59 | 6.62 | 0.81 | 0.79 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 2.26 | 4.22 | 2.99 | 0.44 | 0.53 |
| EV/Core EBITDA(x) | 53.71 | 63.64 | 44.53 | 6.51 | 10.90 |
| EV/EBIT(x) | 81.30 | 89.42 | 53.76 | 8.18 | 16.13 |
| EV/CE(x) | 2.16 | 5.04 | 3.21 | 0.31 | 0.51 |
| M Cap / Sales | 2.25 | 4.20 | 2.99 | 0.41 | 0.47 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 34.19 | -37.39 | 20.41 | 28.37 | 87.12 |
| Core EBITDA Growth(%) | -14.73 | -38.18 | 20.26 | 77.33 | 8.49 |
| EBIT Growth(%) | -20.84 | -46.88 | 25.24 | 108.80 | 2.59 |
| PAT Growth(%) | -19.76 | -43.74 | 2.83 | 150.30 | 2.46 |
| EPS Growth(%) | -19.76 | -43.73 | 2.83 | 150.30 | 2.46 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.03 | 0.03 | 0.03 | 0.08 | 0.12 |
| Current Ratio(x) | 1.63 | 6.23 | 1.40 | 1.17 | 1.32 |
| Quick Ratio(x) | 1.54 | 5.37 | 1.14 | 1.11 | 1.20 |
| Interest Cover(x) | 19.66 | 26.00 | 29.18 | 12.96 | 4.70 |
| Total Debt/Mcap(x) | 0.01 | - | - | 0.10 | 0.15 |
Compare Financial Ratios of peers of BIOFIL CHEMICALS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BIOFIL CHEMICALS & PHARMACEUTICALS | ₹110.3 Cr | -3% | -0.7% | 51.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹361,916.0 Cr | 0.3% | -7.5% | 53.9% | Stock Analytics | |
| CIPLA | ₹115,034.0 Cr | 1.1% | -4.8% | 56.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,929.0 Cr | 1.6% | 1.6% | 27.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹104,873.0 Cr | -1.9% | 10.7% | 21.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹100,322.0 Cr | 5.2% | -0.2% | 90.1% | Stock Analytics | |
BIOFIL CHEMICALS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOFIL CHEMICALS & PHARMACEUTICALS | -3% |
-0.7% |
51.2% |
| SENSEX | -0.6% |
0.3% |
21.8% |
You may also like the below Video Courses
